Bank of America’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Bank of America's CASC Position: Q1 2018 in Review

Bank of America sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 49,802 shares — an estimated $184K sold.

Bank of America first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $192K in Q2 2013. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

• Bank of America reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
• Bank of America sold 49,802 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $184K.
• Bank of America first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
• Bank of America's Cascadian Therapeutics, Inc. position peaked at $192K in Q2 2013.
• 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Bank of America's 13F filing for Q1 2018, filed 15 May 2018.